Mazdutide

IBI362 · LY3305677 · Innovent/Lilly dual agonist

Weight LossInvestigationalPhase IIIResearchSubQ

Popular for:Weight loss, dual GLP-1/glucagon agonist, Chinese-developed obesity drug

31

Registered Trials

6

Trial Publications

38

PubMed References

Phase III

Evidence Level

Overview

Mazdutide is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly, currently in Phase III clinical trials. The short version: people usually care about it for weight loss, dual glp-1/glucagon agonist, chinese-developed obesity drug, but the strength of the evidence depends heavily on indication and study type.

Mazdutide is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly, currently in Phase III clinical trials. It is one of several next-generation obesity drugs competing in the dual/triple agonist space alongside survodutide and retatrutide.

Notably, mazdutide uses bi-weekly (every 2 weeks) dosing rather than weekly, which could be a convenience advantage. Phase II results in Chinese populations showed up to 14.4% weight loss at 24 weeks. It is furthest along in Chinese regulatory pathway and may be among the first dual GLP-1/glucagon agonists to receive approval in any market.

Research Snapshot

What the evidence says

Phase III

Mazdutide currently shows 31 registered trials from ClinicalTrials.gov, 6 PubMed trial publications (6 RCT-tagged), and 38 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.

Known vs uncertain

Known signals

  • 31 registered trials are tracked from ClinicalTrials.gov intervention records.
  • 6 PubMed clinical-trial publications are indexed.
  • 6 PubMed randomized controlled trial publications are indexed.
  • 38 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.

Open questions

  • Evidence strength may vary by indication, route, formulation, and population.
  • Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
  • Regulatory status and compounding access can change independently from the research literature.

Mechanism of Action

Mazdutide activates both GLP-1 and glucagon receptors, similar to survodutide.

Key Research Benefits

Bi-weekly dosing — most convenient dosing schedule in the class
Up to 14.4% weight loss in Phase II (24 weeks)
Dual GLP-1/glucagon mechanism targets liver fat
Advanced in Chinese regulatory pathway
Backed by Eli Lilly partnership

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

31

Registered Trials

6

Trial Publications

6

RCT Publications

38

PubMed References

ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026

Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.

31

Registered trials

6

Trial publications

6

RCT publications

38

PubMed references

21

Reviews

6

Meta-analyses

Registered trials source

Jun 1, 2026

Mazdutide

Uses the exact compound name as a ClinicalTrials.gov intervention query.

View source

Publication counts source

May 3, 2026

Mazdutide

Uses the exact display name.

View source

Investigational — Phase III in China, Phase II globally. Co-developed by Innovent Biologics and Eli Lilly. May receive Chinese approval before US/EU submission.

Key PubMed References

38 PubMed references · showing top 25 by relevance

View all on PubMed

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.

Review

Abdul Fasi M · Expert opinion on therapeutic patents · 2026

PMID: 41820018

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Review

Son JW, le Roux CW, Blüher M, et al. · Endocrine reviews · 2026

PMID: 41054801

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Human Study

Guo L, Zhang B, Xue X, et al. · Nature · 2026

PMID: 41407860

Obesity in China: current progress and future prospects.

Review

Pan XF, Fang ZZ, Zhang L, et al. · The lancet. Diabetes & endocrinology · 2026

PMID: 41389801

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Human Study

Zhu D, Zhao J, Cai H, et al. · Nature · 2026

PMID: 41407859

Anecdotes & Sentiment

Public discussion, not clinical evidence

This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.

No curated public-discussion themes are live for Mazdutide yet.

Side Effects & Safety

- GI side effects (nausea, diarrhea, vomiting) — class effect - Decreased appetite - Injection site reactions - Full safety profile not yet established

GI side effects (nausea, diarrhea, vomiting) — class effect
Decreased appetite
Injection site reactions
Full safety profile not yet established

Known Interactions

No curated interaction entry is live for Mazdutide yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Comparison Pages

Comparison pages

All

No comparison page is linked yet.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.